STEPHEN PENEPACKER: Open Payments
NPI 1336165125 · SAN LUIS OBISPO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,571 in 83 payments from 10 companies in 2025. Trend: 2023 $399 · 2024 $1,226 · 2025 $1,571
Food & beverage: $1,528Education: $43
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $287 |
| ABBVIE INC. | 17 | $243 |
| Alkermes, Inc. | 9 | $229 |
| E.R. Squibb & Sons, L.L.C. | 19 | $229 |
| Teva Pharmaceuticals USA, Inc. | 6 | $152 |
| Lundbeck LLC | 7 | $145 |
| Otsuka America Pharmaceutical, Inc. | 6 | $124 |
| Janssen Pharmaceuticals, Inc | 4 | $119 |
| Almatica Pharma LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, COBENFY, ABILIFY ASIMTUFII, UZEDY, INVEGA SUSTENNA, REXULTI.
Industry payments across CA — which companies pay providers there.
